| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52fcdbfd1e64be1ce60a624089be3689 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_216f572ffddd19a2b63a399db593c1d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b073ab52d8efde367beabad2b2b78f6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be594a8900b9988a478a396fcfe176ad |
| publicationDate |
2019-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109206515-A |
| titleOfInvention |
A kind of Human anti-human interleukin-17 A antibody and its application |
| abstract |
The invention discloses a kind of Human anti-human interleukin-17 A antibody.The antibody includes heavy chain variable region and/or light chain variable region；The heavy chain variable region is a): its amino acid sequence as shown in SEQ ID NO.1, encode its nucleotide sequence preferably as shown in SEQ ID NO.8 or b): it is described a) in the change of people heavy chain framework regions after heavy chain variable region；The light chain variable region is a): its amino acid sequence as shown in SEQ ID NO.2, encode its nucleotide sequence preferably as shown in SEQ ID NO.9 or b): it is described a) in the change of people light chain framework region after light chain variable region.The human antibody molecules for the completely new IL-17A that the present invention obtains, which have, inhibits IL-17A related biological activities；It can treat IL-17A related disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113631574-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021018191-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113121684-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113121684-B |
| priorityDate |
2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |